Xencor (XNCR) Lifted to “Strong-Buy” at BidaskClub
Xencor (NASDAQ:XNCR) was upgraded by investment analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report issued on Friday.
XNCR has been the topic of several other research reports. Cantor Fitzgerald initiated coverage on shares of Xencor in a report on Thursday, February 22nd. They issued a “buy” rating and a $33.00 price target on the stock. Zacks Investment Research raised shares of Xencor from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $35.00 price objective on shares of Xencor in a research note on Sunday, November 12th. Two research analysts have rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $34.25.
Shares of Xencor (NASDAQ:XNCR) opened at $32.72 on Friday. Xencor has a fifty-two week low of $18.55 and a fifty-two week high of $33.00.
Several institutional investors and hedge funds have recently made changes to their positions in XNCR. Great West Life Assurance Co. Can lifted its stake in shares of Xencor by 158.9% during the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 4,005 shares during the period. Principal Financial Group Inc. purchased a new position in shares of Xencor during the third quarter valued at approximately $201,000. UBS Asset Management Americas Inc. purchased a new position in shares of Xencor during the fourth quarter valued at approximately $205,000. Landscape Capital Management L.L.C. purchased a new position in shares of Xencor during the fourth quarter valued at approximately $220,000. Finally, Two Sigma Advisers LP purchased a new position in shares of Xencor during the fourth quarter valued at approximately $278,000. 78.08% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Xencor (XNCR) Lifted to “Strong-Buy” at BidaskClub” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/03/11/xencor-xncr-lifted-to-strong-buy-at-bidaskclub.html.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.